Renibus Therapeutics, a Southlake, TX-based clinical-stage biopharmaceutical company, received $47M from the initial closings of a Series B financing.
The backers were not disclosed.
The company intends to use the funds to advance RBT-1 through a pivotal Phase 3 trial for its lead indication of reducing the risk of post-operative complications following cardiothoracic surgery.
Led by Co-CEOs Frank Stonebanks, and D. Jeff Keyser, RPh, JD, PhD, Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal diseases and complex surgeries. It has developed a portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning.
Its lead program RBT-1 is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. RBT-2 is an antioxidant and anti-fibrotic drug that has been shown in pre-clinical models to have the potential to reduce the risk of CKD progression. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve anemia and reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated the RBT-9 has the potential to improve clinical outcomes in life threatening viral infections.
FinSMEs
19/07/2023